Overview

OXiGENE, Inc., a Boston-based developer of cancer drugs, has taken advantage of information technology (IT) and strategic outsourcing hoping to reduce the long lead times, high costs, and high risks associated with pharmaceutical development. With only ten full-time employees, OXiGENE operated as a virtual corporation that in-licenses promising drug candidates from R&D institutions and develops them to an intermediate clinical stage. The company then either partners with major pharmaceutical manufacturers to further develop the drug candidate, or sells the rights to another party. This report describes how OXiGENE leveraged IT in the areas of information management as well as computer simulation and modeling.   It also describes how OXiGENE's small, mobile and modular approach to development takes advantage of the best capabilities of strategic outsourcing partners, while their small size allows them to respond flexibly and rapidly to technological change.
(5 pages)

You have attempted to access an area of the Management Roundtable site that requires you to be signed in or to have a different level of access.

Please log in with your email address and password below. If you are not a member, you may join Management Roundtable for additional benefits.

E-mail

Password Sign in

Forgotten your password? Click here to request your password

SPECIAL NO-RISK OFFER

Now you can try FastTrack for yourself. For just $89, you can access everything on FastTrack for 6 weeks. At the end of your introductory membership, you can renew your membership for a full year at the regular rate of $495 per year. If you're not 100% satisfied with your membership, simply contact us to receive a full refund!
 

OPTION 1	OPTION 2
OPTION 3 Not ready to commit yet? Become a registered user of Fast Track for free. Every month we make exclusive Fast Track articles available to our registered users.

 

 

---